Humanigen latest to boast of COVID-19 drug prospects

15 May 2020

US biotech Humanigen (OTCMKTS: HGEN) has announced that the first COVID-19 patient has been dosed in its trial of lenzilumab, the company’s anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

It is the first Phase III pivotal study of an anti GM-CSF monoclonal antibody in COVID-19 patients with Humanigen optimistic because of the drug’s performance in compassionate use patients.

Another positive, given the urgent need for treatments, has been the speed with which the program has moved through US Food and Drug Administration approval and site activation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK